Microvesicles in Atherosclerosis and Angiogenesis: From Bench to Bedside and Reverse

被引:65
|
作者
Badimon, Lina [1 ,2 ,3 ]
Suades, Rosa [1 ,2 ]
Arderiu, Gemma [1 ,2 ]
Pena, Esther [1 ,2 ]
Chiva-Blanch, Gemma [1 ,2 ]
Padro, Teresa [1 ,2 ]
机构
[1] St Pau Biomed Res Inst IIB St Pau, Cardiovasc Res Ctr ICCC, Barcelona, Spain
[2] St Pau Biomed Res Inst IIB St Pau, CiberCV, Barcelona, Spain
[3] UAB, Cardiovasc Res Chair, Barcelona, Spain
来源
FRONTIERS IN CARDIOVASCULAR MEDICINE | 2017年 / 4卷
关键词
angiogenesis; atherosclerosis; cardiovascular diseases; cell-derived microvesicles; endothelial dysfunction; inflammation; neovascularization; thrombosis; PLATELET-DERIVED MICROPARTICLES; CIRCULATING ENDOTHELIAL MICROPARTICLES; MESENCHYMAL STEM-CELLS; SMOOTH-MUSCLE-CELLS; TYPE-2; DIABETES-MELLITUS; SHED MEMBRANE MICROPARTICLES; MONOCYTE ACTIVATION MARKERS; BLOOD-BORNE MICROPARTICLES; SOLUBLE ADHESION MOLECULES; HIGH CARDIOVASCULAR RISK;
D O I
10.3389/fcvm.2017.00077
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atherosclerosis (AT) is a progressive chronic disease involving lipid accumulation, fibrosis, and inflammation in medium and large-sized arteries, and it is the main cause of cardiovascular disease (CVD). AT is caused by dyslipidemia and mediated by both innate and adaptive immune responses. Despite lipid-lowering drugs have shown to decrease the risk of cardiovascular events (CVEs), there is a significant burden of AT-related morbidity and mortality. Identification of subjects at increased risk for CVE as well as discovery of novel therapeutic targets for improved treatment strategies are still unmet clinical needs in CVD. Microvesicles (MVs), small extracellular plasma membrane particles shed by activated and apoptotic cells have been widely linked to the development of CVD. MVs from vascular and resident cells by facilitating exchange of biological information between neighboring cells serve as cellular effectors in the bloodstream and play a key role in all stages of disease progression. This article reviews the current knowledge on the role of MVs in AT and CVD. Attention is focused on novel aspects of MV-mediated regulatory mechanisms from endothelial dysfunction, vascular wall inflammation, oxidative stress, and apoptosis to coagulation and thrombosis in the progression and development of atherothrombosis. MV contribution to vascular remodeling is also discussed, with a particular emphasis on the effect of MVs on the crosstalk between endothelial cells and smooth muscle cells, and their role regulating the active process of AT-driven angiogenesis and neovascularization. This review also highlights the latest findings and main challenges on the potential prognostic, diagnostic, and therapeutic value of cell-derived MVs in CVD. In summary, MVs have emerged as new regulators of biological functions in atherothrombosis and might be instrumental in cardiovascular precision medicine; however, significant efforts are still needed to translate into clinics the latest findings on MV regulation and function.
引用
收藏
页数:20
相关论文
共 50 条
  • [31] From Pathogenesis to Therapy in Knee Osteoarthritis: Bench-to-Bedside
    Rezus, Elena
    Burlui, Alexandra
    Cardoneanu, Anca
    Macovei, Luana Andreea
    Tamba, Bogdan Ionel
    Rezus, Ciprian
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (05) : 1 - 24
  • [32] COVID-19 and Cardiovascular Disease From Bench to Bedside
    Chung, Mina K.
    Zidar, David A.
    Bristow, Michael R.
    Cameron, Scott J.
    Chan, Timothy
    Harding, Clifford V., III
    Kwon, Deborah H.
    Singh, Tamanna
    Tilton, John C.
    Tsai, Emily J.
    Tucker, Nathan R.
    Barnard, John
    Loscalzo, Joseph
    CIRCULATION RESEARCH, 2021, 128 (08) : 1214 - 1236
  • [33] Cell therapies for therapeutic angiogenesis: back to the bench
    Sieveking, Daniel P.
    Ng, Martin K. C.
    VASCULAR MEDICINE, 2009, 14 (02) : 153 - 166
  • [34] Characteristics of erythrocyte-derived microvesicles and its relation with atherosclerosis
    Li, Kai-Yin
    Zheng, Lei
    Wang, Qian
    Hu, Yan-Wei
    ATHEROSCLEROSIS, 2016, 255 : 140 - 144
  • [35] GPIIb/IIIa inhibitors: From bench to bedside and back to bench again
    Armstrong, Paul C.
    Peter, Karlheinz
    THROMBOSIS AND HAEMOSTASIS, 2012, 107 (05) : 808 - 814
  • [36] ANGIOGENESIS IN ATHEROSCLEROSIS
    KAHLON, R
    SHAPERO, J
    GOTLIEB, AI
    CANADIAN JOURNAL OF CARDIOLOGY, 1992, 8 (01) : 60 - 64
  • [37] From bench to bedside - translational research in psoriasis
    Prinz, J. C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 : 1 - 4
  • [38] Diabetes and antiplatelet therapy: from bench to bedside
    Rios, Jose R. Rivas
    Franchi, Francesco
    Rollini, Fabiana
    Angiolillo, Dominick J.
    CARDIOVASCULAR DIAGNOSIS AND THERAPY, 2018, 8 (05) : 594 - 609
  • [39] From bench to bedside: Bacterial growth and cytokines
    Dos Santos C.C.
    Zhang H.
    Slutsky A.S.
    Critical Care, 6 (1): : 4 - 6
  • [40] Angioprevention in Colon Cancer from Bench to Bedside
    Temraz, Sally
    Alameddine, Raafat
    Shamseddine, Ali
    CURRENT COLORECTAL CANCER REPORTS, 2015, 11 (06) : 422 - 431